6:25 PM
 | 
Dec 12, 2012
 |  BC Extra  |  Company News

J&J submits NDA for fixed-dose diabetes product

Janssen Research & Development LLC submitted an NDA to FDA for a fixed-dose combination of canagliflozin and immediate-release metformin to treat Type II...

Read the full 92 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >